author={Atsunori Fukuhara and Morihiro Matsuda and Masako Nishizawa and Katsumori Segawa and Masaki Tanaka and Kae Kishimoto and Yasushi Matsuki and Mirei Murakami and Tomoko Ichisaka and Hiroko Murakami and Eijiro Watanabe and Toshiyuki Takagi and Megumi Akiyoshi and Tsuguteru Ohtsubo and Shinji Kihara and Shizuya Yamashita and Makoto Makishima and Tohru Funahashi and Shinya Yamanaka and Ryuji Hiramatsu and Yuji Matsuzawa and Iichiro Shimomura},
  pages={565 - 565}
7 Citations
Adipocytokines visfatin and resistin in breast cancer: Clinical relevance, biological mechanisms, and therapeutic potential.
The clinical association of circulating visfatin and resistin with breast cancer and their biological mechanisms are reviewed, in addition to their role in the context of tumor-stromal interactions in the breast cancer microenvironment. Expand
The Cytokine Nicotinamide Phosphoribosyltransferase (eNAMPT; PBEF; Visfatin) Acts as a Natural Antagonist of C-C Chemokine Receptor Type 5 (CCR5)
The work shows that eNAMPT binds to CCR5 and acts as a natural antagonist of this receptor, suggesting that it acts through a putative receptor, although its nature is still elusive. Expand
Visfatin: A Possible Role in Cardiovasculo-Metabolic Disorders
Visfatin/NAMPT appears to be a unique molecule with clinical significance with a prospective promising diagnostic, prognostic, and therapeutic applications in many cardiovasculo-metabolic disorders. Expand
Extracellular Vesicle-Contained eNAMPT Delays Aging and Extends Lifespan in Mice.
It is shown that the circulating levels of extracellular nicotinamide phosphoribosyltransferase (eNAMPT) significantly decline with age in mice and humans, and a novel EV-mediated delivery mechanism is revealed which promotes systemic NAD+ biosynthesis and counteracts aging, suggesting a potential avenue for anti-aging intervention in humans. Expand
Visfatin Connection: Present and Future in Osteoarthritis and Osteoporosis
Basic and clinical data are brought together regarding the common role of visfatin in these pathologies and their major shared risk factors to discuss the pitfalls of visFatin as a potential biomarker and therapeutic target in both pathologies. Expand
Visfatin as a therapeutic target for rheumatoid arthritis
The repurposing of cancer-tested drugs to inhibit visfatin in the context of RA and the possibility of combining these drugs with current RA therapy are addressed, and the future of visFatin as an RA biomarker or therapeutic target is explored. Expand
New insights into adipokines as potential biomarkers for type-2 diabetes mellitus.
The possible use of recent described adipokines, including apelin, omentin-1, resistin, FGF-21, neuregulin-4 and visfatin, as early biomarkers for diabetes are discussed. Expand